TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11601765

Group type: COMPARATOR
Intervention: Group A: Fourth generation dentine‐bonding agent and composite restoration (control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group B: Paste composed of sodium perborate and hydrogen peroxide for 7 days, sealed with glass ionomer cement
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group C: Paste of sodium perborate and hydrogen peroxide for 7 days, followed by calcium hydroxide paste for 1 week
Number of subjects: 30
Study: 9811915

Group type: EXPERIMENTAL
Intervention: Zidovudine prophylaxis started in the prenatal period
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Zidovudine prophylaxis started intra partum
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Zidovudine prophylaxis started within the first 48 hours of life
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Zidovudine prophylaxis started on day 3 of life or later
Number of subjects: 939

Group type: COMPARATOR
Intervention: No zidovudine prophylaxis
Number of subjects: 939
Study: 8080372

Group type: EXPERIMENTAL
Intervention: Conservative, nonexcisional therapy (meticulous hair control by natal cleft shaving, improved perineal hygiene, limited lateral incision and drainage for abscess)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Excisional procedures
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 330
Study: 2609140

Group type: EXPERIMENTAL
Intervention: Trichlormethiazide 4 mg/d
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Trichlormethiazide and amiloride 2 mg/d each
Number of subjects: 25
Study: 4947491

Group type: EXPERIMENTAL
Intervention: Various drug combinations and dosages; treatment duration and rhythms; drug toxicity prevention; home treatment vs. sanatorium treatment; routine home visiting; pretreatment sensitivity tests; short (6-month) intensive courses vs. long-term (18-month) standard courses
Number of subjects: 0
Study: 31004286

Group type: EXPERIMENTAL
Intervention: 0.5% carbomer 980 gel
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 30577785

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) performed in 66 patients by applying an upper arm blood pressure cuff inflated four times for 5 min to 50 mmHg above systolic blood pressure, followed by deflation for 5 min
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group with blood pressure cuff inflated only to 10 mmHg below the patient's diastolic blood pressure
Number of subjects: 132
Study: 27381253

Group type: EXPERIMENTAL
Intervention: 24 IU of intranasal OXT
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 24202712

Group type: EXPERIMENTAL
Intervention: Occult-scar incision laparoscopic cholecystectomy (OSLC)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Classic three-port laparoscopic cholecystectomy (CLC)
Number of subjects: 75
Study: 21848408

Group type: EXPERIMENTAL
Intervention: Indirect bonding technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional direct-bonding technique
Number of subjects: 30
Study: 18485261

Group type: EXPERIMENTAL
Intervention: Duloxetine 20 mg
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Duloxetine 60-120 mg
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 75-225 mg
Number of subjects: 581

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 581
Study: 17848625

Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg/day
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Higher aspirin doses (162 mg and 325 mg)
Number of subjects: 120
Study: 14693632

Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 64

Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 64
Study: 11679505

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (800 microg)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Oral misoprostol (800 microg)
Number of subjects: 201
Study: 9509846

Group type: EXPERIMENTAL
Intervention: Stress management program (health education, muscle relaxation, back massage)
Number of subjects: 40
Study: 8205582

Group type: EXPERIMENTAL
Intervention: Colgate Platinum Professional Toothwhitening System
Number of subjects: 70

Group type: COMPARATOR
Intervention: Rembrandt Gel Plus
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo paste
Number of subjects: 70
Study: 2643864

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 4619059

Group type: EXPERIMENTAL
Intervention: Mefloquine hydrochloride (WR 142490), single dose
Number of subjects: 0
Study: 30260740

Group type: EXPERIMENTAL
Intervention: EPA-rich fish oil (600 mg EPA and 260 mg DHA per day for 8 weeks)
Number of subjects: 16
Study: 28448329

Group type: EXPERIMENTAL
Intervention: Educational program (individualized education session, self-care manual, and weekly phone calls)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 144
Study: 25678402

Group type: EXPERIMENTAL
Intervention: PtCr‐PES
Number of subjects: 0

Group type: COMPARATOR
Intervention: TE‐PES
Number of subjects: 0

Group type: COMPARATOR
Intervention: BMS
Number of subjects: 0
Study: 24089434

Group type: EXPERIMENTAL
Intervention: Action observational training (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 30
Study: 21106710

Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) 5 mg/d for children < 40 kg and 10 mg/d for children ≥ 40 kg
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 18210952

Group type: EXPERIMENTAL
Intervention: High compression therapy plus amelogenin
Number of subjects: 83

Group type: COMPARATOR
Intervention: High compression therapy alone
Number of subjects: 83
Study: 17109671

Group type: EXPERIMENTAL
Intervention: Pramlintide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14667945

Group type: COMPARATOR
Intervention: Obstacle crossing (2.5%, 5%, 10%, and 15% of height)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Increased M-L motion of the COM during obstacle crossing
Number of subjects: 15
Study: 10960405

Group type: COMPARATOR
Intervention: 0% N(2)O (Air)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 30% N(2)O (N30)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 40% N(2)O (N40)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 50% N(2)O (N50)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 67% N(2)O (N67)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 40% N(2)O (N40-a)
Number of subjects: 125
Study: 9395642

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8192301

Group type: EXPERIMENTAL
Intervention: Small clinical trials
Number of subjects: 0
Study: 3569028

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 900 mg iv q8h (treatment C)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 600 mg iv q6h (treatment A)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Clindamycin phosphate 600 mg iv q8h (treatment B)
Number of subjects: 6
Study: 29783893

Group type: EXPERIMENTAL
Intervention: Real-tDCS
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham-tDCS
Number of subjects: 35
Study: 24893766

Group type: EXPERIMENTAL
Intervention: LKM512
Number of subjects: 44

Group type: COMPARATOR
Intervention: KYNA injection
Number of subjects: 44
Study: 23147329

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine 1:100,000 (L100)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 4% articaine with epinephrine 1:200,000 (A200)
Number of subjects: 43
Study: 20545244

Group type: EXPERIMENTAL
Intervention: Agua das Pedras (sodium-rich carbonated mineral water), 500 ml/day for 7 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Agua Vitalis (control), 500 ml/day for 7 weeks
Number of subjects: 17
Study: 18833588

Group type: EXPERIMENTAL
Intervention: Patient-focused educational resource (filofax-style folder with inserts)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no educational resource)
Number of subjects: 32
Study: 16278522

Group type: EXPERIMENTAL
Intervention: Thiazide-type diuretics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other antihypertensive drug classes
Number of subjects: 0
Study: 12412675

Group type: EXPERIMENTAL
Intervention: Fluticasone (100 microg b.i.d.)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg, once a day)
Number of subjects: 40
Study: 10341919

Group type: EXPERIMENTAL
Intervention: Drainage (n = 43)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No drainage (n = 57)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 8547195

Group type: EXPERIMENTAL
Intervention: Intensive follow-up group (6 monthly chest X-rays and bone scans)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (clinical examination only)
Number of subjects: 0
Study: 2403473

Group type: EXPERIMENTAL
Intervention: Computer-administered cognitive-behavioral treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapist-administered cognitive-behavioral treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 0
Study: 28102

Group type: EXPERIMENTAL
Intervention: Standard neuroleptics
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Pipotiazine palmitate
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate
Number of subjects: 181
Study: 30581069

Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX (D1 bolus removed)
Number of subjects: 188

Group type: COMPARATOR
Intervention: CisGem (Cisplatin and Gemcitabine)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX
Number of subjects: 188
Study: 27022941

Group type: EXPERIMENTAL
Intervention: Fast feeding
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Slow feeding
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Post-operative state
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pre-operative state
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Food intake
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy
Number of subjects: 10
Study: 26189253

Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiotherapy (IMRT) with concurrent chemotherapy (nedaplatin 30 mg/m2 weekly for six cycles)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Three-Dimensional Conformal Radiotherapy (3D CRT) with concurrent chemotherapy (nedaplatin 30 mg/m2 weekly for six cycles)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both IMRT and 3D CRT groups
Number of subjects: 72
Study: 23656836

Group type: EXPERIMENTAL
Intervention: Incentive strategy promoting adherence to laboratory confirmation of malaria before treatment at facility-level
Number of subjects: 18
Study: 21451017

Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivariate pattern analysis methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decoding stimulus attributes and cognitive states from fMRI measurements
Number of subjects: 0
Study: 19089321

Group type: EXPERIMENTAL
Intervention: Loratadine/Montelukast (L/M) 10 mg/10 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Diphenhydramine 50 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 16772315

Group type: EXPERIMENTAL
Intervention: Advanced mandibular advancement device (MAD)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Non-advanced mandibular advancement device (MAD)
Number of subjects: 23
Study: 15557944

Group type: EXPERIMENTAL
Intervention: Stent with windsock-type antireflux valve (FerX-Ella) (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard open stent (n = 15)
Number of subjects: 30
Study: 11535842

Group type: EXPERIMENTAL
Intervention: Oral diltiazem (60 mg, twice daily for up to eight weeks)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Topical diltiazem (2 percent gel, twice daily for up to eight weeks)
Number of subjects: 50
Study: 9024445

Group type: EXPERIMENTAL
Intervention: HAB (Histoacryl Blue)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 61
Study: 8394651

Group type: COMPARATOR
Intervention: MCPP (0.35 mg/kg p.o.)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Clozapine (up to 600 mg/day for 5 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: MCPP
Number of subjects: 19
Study: 3314538

Group type: EXPERIMENTAL
Intervention: Bilateral ECT
Number of subjects: 52

Group type: COMPARATOR
Intervention: Unilateral right ECT
Number of subjects: 52
Study: 29903845

Group type: EXPERIMENTAL
Intervention: Baseline adiponectin
Number of subjects: 6998

Group type: EXPERIMENTAL
Intervention: Change in adiponectin from baseline to month 3
Number of subjects: 6998

Group type: EXPERIMENTAL
Intervention: Baseline FFAs
Number of subjects: 6998

Group type: EXPERIMENTAL
Intervention: Change in FFAs from baseline
Number of subjects: 6998
Study: 27044585

Group type: EXPERIMENTAL
Intervention: HIIT and nutrition advice
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MICT and nutrition advice
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nutrition advice
Number of subjects: 100
Study: 23363371

Group type: EXPERIMENTAL
Intervention: Wii Fit intervention (10 min thrice weekly for 1 month)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Regular Jump Ahead programme (comparison group)
Number of subjects: 18
Study: 22926339

Group type: EXPERIMENTAL
Intervention: High-resolution microendoscope (HRME) imaging system
Number of subjects: 174

Group type: COMPARATOR
Intervention: Visual inspection with acetic acid (VIA) and colposcopic examination
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: High-risk human papilloma virus (HPV) DNA testing
Number of subjects: 174
Study: 20438354

Group type: EXPERIMENTAL
Intervention: AH Plus
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Epiphany (hand mixed)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Epiphany (automix syringe)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Apexit Plus
Number of subjects: 128

Group type: COMPARATOR
Intervention: 17% EDTAC
Number of subjects: 128

Group type: COMPARATOR
Intervention: Er:YAG laser
Number of subjects: 128

Group type: COMPARATOR
Intervention: 1% NaOCl
Number of subjects: 128

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 128
Study: 18656328

Group type: EXPERIMENTAL
Intervention: 10 mg of enalapril plus 0.4 mg of folic acid (low‐FA group)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 10 mg of enalapril plus 0.8 mg of folic acid (high‐FA group)
Number of subjects: 480

Group type: COMPARATOR
Intervention: 10 mg of enalapril (control group)
Number of subjects: 480
Study: 16301338

Group type: EXPERIMENTAL
Intervention: Weightlessness (acute 20‐s periods in parabolic airplane flights)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Weightlessness (after a week in space)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Seated 1‐G position (reference)
Number of subjects: 12
Study: 12665407

Group type: EXPERIMENTAL
Intervention: Variable-frequency train (VFT) stimulation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Constant-frequency train (CFT) stimulation
Number of subjects: 10
Study: 10811043

Group type: EXPERIMENTAL
Intervention: Penicillin V
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 8711491

Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis (IAT) with low-dose recombinant tissue-type plasminogen activator (rt-PA) (0.02 to 0.05 mg/h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis (IAT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical revascularization
Number of subjects: 0
Study: 1509913

Group type: EXPERIMENTAL
Intervention: Complete hormonal blockade (orchiectomy + flutamide)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Monotherapy (orchiectomy only)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Flutamide (part of complete blockade)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Complete hormonal blockade
Number of subjects: 70

Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 70
Study: 6871626

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol and a balanced electrolyte solution (PEG + E)
Number of subjects: 77
Study: 31659967

Group type: EXPERIMENTAL
Intervention: Flipped classroom model (Group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional didactic lecture (Group A)
Number of subjects: 40
Study: 30278479

Group type: EXPERIMENTAL
Intervention: Biliary drainage (interventional therapy)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Radical/palliative surgery (conventional group)
Number of subjects: 90
Study: 25847473

Group type: EXPERIMENTAL
Intervention: Cocoa extract (CE) ingestion for 3 weeks before and after vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no cocoa ingestion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cocoa extract (CE) ingestion
Number of subjects: 0
Study: 24332423

Group type: EXPERIMENTAL
Intervention: Everolimus-Eluting Stents (EES)
Number of subjects: 1498

Group type: COMPARATOR
Intervention: Bare-Metal Stents (BMS)
Number of subjects: 1498
Study: 22004457

Group type: EXPERIMENTAL
Intervention: Mosapride 5 mg tid
Number of subjects: 618

Group type: COMPARATOR
Intervention: Teprenone 50 mg tid
Number of subjects: 618
Study: 18704618

Group type: EXPERIMENTAL
Intervention: Pre-emptive Bupivacaine (PBU) - 10 ml 0.5% Bupivacaine to port sites before skin incision and another 10 ml to the preperitoneal space immediately after the creation of a first working port.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Standard Bupivacaine (SBU) - Infiltration of Bupivacaine after mesh placement.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (CO) - Saline injection instead of Bupivacaine.
Number of subjects: 90
Study: 17450086

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 24

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 24
Study: 15367189

Group type: EXPERIMENTAL
Intervention: 0.2% CHX spray (test group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.12% CHX mouthrinse (control group)
Number of subjects: 20
Study: 11592918

Group type: EXPERIMENTAL
Intervention: Recombinant P64k (20 or 50 microg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9555822

Group type: EXPERIMENTAL
Intervention: 0.025% tretinoin gel containing polyolprepolymer‐2
Number of subjects: 215

Group type: COMPARATOR
Intervention: 0.025% commercially‐available tretinoin gel
Number of subjects: 215

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Both active medications
Number of subjects: 215
Study: 8275406

Group type: EXPERIMENTAL
Intervention: DPT vaccine (group A, 99 children)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intramuscular pertussis vaccine (group A, 99 children)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: DT vaccine (group B, 101 children)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intramuscular pertussis vaccine
Number of subjects: 200
Study: 2542197

Group type: COMPARATOR
Intervention: Radiation therapy alone (RT) (50 Gy large field and 10 Gy boost)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Radiation therapy combined with misonidazole (400 mg/m2 2‐4 hr prior to RT daily for 5‐6 weeks)
Number of subjects: 268
Study: 29733400

Group type: EXPERIMENTAL
Intervention: ILO once monthly (group B)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: ILO for five consecutive days (group C)
Number of subjects: 96

Group type: COMPARATOR
Intervention: No ILO (group A)
Number of subjects: 96
Study: 28025364

Group type: EXPERIMENTAL
Intervention: Single-Blind Placebo Lead-in (SBPLI)
Number of subjects: 0
Study: 25638597

Group type: EXPERIMENTAL
Intervention: 30 g/day whey protein-supplemented beverage
Number of subjects: 219

Group type: COMPARATOR
Intervention: Energy-matched low-protein high-carbohydrate beverage (control)
Number of subjects: 219
Study: 22818976

Group type: EXPERIMENTAL
Intervention: Distraction osteogenesis (DO) of the mandibular anterior alveolar process
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (orthodontically treated patients)
Number of subjects: 19
Study: 21040143

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (Gamunex)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Gamunex
Number of subjects: 117
Study: 17368909

Group type: EXPERIMENTAL
Intervention: Digital rotation
Number of subjects: 61

Group type: COMPARATOR
Intervention: No intervention (group I)
Number of subjects: 61
Study: 16550750

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (La)
Number of subjects: 1359

Group type: COMPARATOR
Intervention: Standard therapy (any approved phosphate binder)
Number of subjects: 1359
Study: 14972204

Group type: EXPERIMENTAL
Intervention: Standardized patient feedback (SP)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No standardized patient feedback (Control)
Number of subjects: 8
Study: 10981209

Group type: EXPERIMENTAL
Intervention: Self-completed HQL questionnaire
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Telephone interview HQL questionnaire
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Self-completed PDQ-39 Social Support subscale
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Telephone interview PDQ-39 Social Support subscale
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Telephone interview PDQ-39 Cognitions subscale
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Self-completed SF-36 General Health subscale
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Self-completed SF-36 Social Function subscale
Number of subjects: 150

Group type: COMPARATOR
Intervention: Patients at later clinical stages
Number of subjects: 150

Group type: COMPARATOR
Intervention: Patients with dyskinesias
Number of subjects: 150

Group type: COMPARATOR
Intervention: Patients with self-reported comorbidities
Number of subjects: 150
Study: 8783327

Group type: EXPERIMENTAL
Intervention: Celiac plexus block (CPB)
Number of subjects: 21

Group type: COMPARATOR
Intervention: NSAID‐morphine treatment
Number of subjects: 21